Novel PSMA-Targeting Radionuclide Peptidomimetics for Treating Prostate Cancer.

ABSTRACT: Prostate cancer is the third-most commonly diagnosed cancer and is one of the leading causes of cancer-related deaths in men worldwide. Although an armamentarium of approved drugs exists, treatment options become severely limited when resistance develops against last-line taxane chemotherapeutics. In March 2022, the FDA approved a first-in-class targeted radionuclide therapy, lutetium Lu 177 vipivotide tetraxetan (Pluvicto), for treating metastatic castration-resistant prostate cancer. The drug constitutes a prostate-specific membrane antigen-targeting peptidomimetic moiety conjugated to a radionuclide chelator via a linker. This Patent Highlight reveals the structure-activity relationship of key compounds against prostate cancer cells.

SUBMITTER: Chia CSB 

PROVIDER: S-EPMC9841587 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature